Board representative: Heather Vezina
Objective: To enable the use of pharmacometrics to inform decision making within drug discovery, development and clinical practice.
Initial priority will be placed on development of a communications package designed to describe the science of pharmacometrics to external audiences and communities. In parallel to this, the working group will identify key stakeholders for increased engagement over the next 3-5 years. Engagement with the identified stakeholders, such as clinical societies, regulatory agencies, and healthcare payer organizations, is prioritized to first deeply understand their perspective, followed by a systematic and sustainable engagement with those areas.
- By 2023, key stakeholders including regulators, clinicians and other technical disciplines have a robust understanding of the value of pharmacometrics for quantitative decision making.
- In the 1-2 therapeutic areas that have been prioritized for engagement, pharmacometrics is embraced as a core discipline in modern drug development, and is more routinely observed in clinical journals and meetings, thus enabling sustainable contributions beyond this strategic plan.
- By 2023 ISoP has leveraged these experiences to develop a playbook for engaging with additional therapeutic areas following this strategic plan.
Want to help? Volunteer!